Anti-SARS-CoV-2 human antibodies retaining neutralizing activity against SARS-CoV-2 B.1.1.529 (omicron)
Imbrechts, M.; Kerstens, W.; Rasulova, M.; Vercruysse, T.; Maes, W.; Ampofo, L.; Ven, K.; Lammertyn, J.; Vanhoorelbeke, K.; Callewaert, N.; Neyts, J.; Dallmeier, K.; Declerck, P.; Thibaut, H. J.; Geukens, N.
Show abstract
SARS-CoV-2 B.1.1.529, designated omicron, was recently identified as a new variant of concern by WHO and is rapidly replacing SARS-CoV-2 delta as the most dominant variant in many countries. Unfortunately, because of the high number of mutations present in the spike of SARS-CoV-2 omicron, most monoclonal antibodies (mAbs) currently approved for treatment of COVID-19 lose their in vitro neutralizing activity against this variant. We recently described a panel of human anti-SARS-CoV-2 mAbs that potently neutralize SARS-CoV-2 Wuhan, D614G and variants alpha, beta, gamma and delta. In this work, we evaluated our mAb panel for potential in vitro activity against SARS-CoV-2 delta and omicron. Three mAbs from our panel retain neutralizing activity against both delta and omicron, with mAb 3B8 still resulting in complete neutralization at a concentration as low as 0.02 g/ml for both variants. Overall, our data indicate that mAb 3B8 may have the potential to become a game-changer in the fight against the continuously evolving SARS-CoV-2.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A novel biparatopic antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy 95%
- Development of Potent and Effective Synthetic SARS-CoV-2 Neutralizing Nanobodies 94%
- Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological and pathological disease in a Syrian hamster model of COVID-19 93%
Similar papers in this journal
- XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 Spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants. 95%
- Systematical assessment of the impact of single spike mutations of SARS-CoV-2 Omicron sub-variants on the neutralization capacity of post-vaccination sera 94%
- Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants 94%
Similar papers in this journal
- Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodies 96%
- A potently neutralizing and protective human antibody targeting antigenic site V on RSV and hMPV fusion glycoprotein 94%
- Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects Macaques from infection 93%
Similar papers in this journal
- An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV 93%
- One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization 92%
- SARS-CoV-2 Omicron BA.2.87.1 Exhibits Higher Susceptibility to Serum Neutralization Than EG.5.1 and JN.1 92%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.